» Articles » PMID: 34749013

Metabolic Therapy and Bioenergetic Analysis: The Missing Piece of the Puzzle

Overview
Journal Mol Metab
Specialty Cell Biology
Date 2021 Nov 8
PMID 34749013
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Aberrant metabolism is recognized as a hallmark of cancer, a pillar necessary for cellular proliferation. Regarding bioenergetics (ATP generation), most cancers display a preference not only toward aerobic glycolysis ("Warburg effect") and glutaminolysis (mitochondrial substrate level-phosphorylation) but also toward other metabolites such as lactate, pyruvate, and fat-derived sources. These secondary metabolites can assist in proliferation but cannot fully cover ATP demands.

Scope Of Review: The concept of a static metabolic profile is challenged by instances of heterogeneity and flexibility to meet fuel/anaplerotic demands. Although metabolic therapies are a promising tool to improve therapeutic outcomes, either via pharmacological targets or press-pulse interventions, metabolic plasticity is rarely considered. Lack of bioenergetic analysis in vitro and patient-derived models is hindering translational potential. Here, we review the bioenergetics of cancer and propose a simple analysis of major metabolic pathways, encompassing both affordable and advanced techniques. A comprehensive compendium of Seahorse XF bioenergetic measurements is presented for the first time.

Major Conclusions: Standardization of principal readouts might help researchers to collect a complete metabolic picture of cancer using the most appropriate methods depending on the sample of interest.

Citing Articles

Metabolic crossroads: unravelling immune cell dynamics in gastrointestinal cancer drug resistance.

Suri C, Pande B, Suhasini Sahithi L, Swarnkar S, Khelkar T, Verma H Cancer Drug Resist. 2025; 8:7.

PMID: 40051496 PMC: 11883236. DOI: 10.20517/cdr.2024.164.


Successful application of dietary ketogenic metabolic therapy in patients with glioblastoma: a clinical study.

Kiryttopoulos A, Evangeliou A, Katsanika I, Boukovinas I, Foroglou N, Zountsas B Front Nutr. 2025; 11:1489812.

PMID: 40041752 PMC: 11876051. DOI: 10.3389/fnut.2024.1489812.


Hyaluronic Acid Influences Amino Acid Metabolism via Differential L-Type Amino Acid Transporter 1 Expression in the U87-Malignant Glioma Cell Line.

Bale A, Thammineni S, Bhargava R, Harley B Adv Nanobiomed Res. 2025; 4(12).

PMID: 40017591 PMC: 11864772. DOI: 10.1002/anbr.202400107.


Unlocking the Heterogeneity in Acute Leukaemia: Dissection of Clonal Architecture and Metabolic Properties for Clinical Interventions.

Capelletti M, Montini O, Ruini E, Tettamanti S, Savino A, Sarno J Int J Mol Sci. 2025; 26(1.

PMID: 39795903 PMC: 11719665. DOI: 10.3390/ijms26010045.


Clinical research framework proposal for ketogenic metabolic therapy in glioblastoma.

Duraj T, Kalamian M, Zuccoli G, Maroon J, DAgostino D, Scheck A BMC Med. 2024; 22(1):578.

PMID: 39639257 PMC: 11622503. DOI: 10.1186/s12916-024-03775-4.


References
1.
Sapandowski A, Stope M, Evert K, Evert M, Zimmermann U, Peter D . Cardiolipin composition correlates with prostate cancer cell proliferation. Mol Cell Biochem. 2015; 410(1-2):175-85. DOI: 10.1007/s11010-015-2549-1. View

2.
Potter M, Newport E, Morten K . The Warburg effect: 80 years on. Biochem Soc Trans. 2016; 44(5):1499-1505. PMC: 5095922. DOI: 10.1042/BST20160094. View

3.
Hiller K, Metallo C, Kelleher J, Stephanopoulos G . Nontargeted elucidation of metabolic pathways using stable-isotope tracers and mass spectrometry. Anal Chem. 2010; 82(15):6621-8. DOI: 10.1021/ac1011574. View

4.
Magee B, Potezny N, Rofe A, Conyers R . The inhibition of malignant cell growth by ketone bodies. Aust J Exp Biol Med Sci. 1979; 57(5):529-39. DOI: 10.1038/icb.1979.54. View

5.
Thakur N, Sharma A, Singh H, Singh S . Role of Mitochondrial DNA (mtDNA) Variations in Cancer Development: A Systematic Review. Cancer Invest. 2020; 38(7):375-393. DOI: 10.1080/07357907.2020.1797768. View